Compare Amplitude Inc (AMPL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs BioNano Genomics Inc — how do they compare? Amplitude Inc trades at $12.56 (market cap $1.59B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Amplitude Inc is far larger — about 116.4× BioNano Genomics Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | BNGO | |
|---|---|---|
Market Cap | $1.59B | $13.66M |
Sector | Technology | Health |
52-Week High | $12.69 | $4.92 |
52-Week Low | $5.61 | $1.06 |
Enterprise Value | $1.45B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $12.38, up 1.56% with bullish technical signals from moving averages and ADX indicators. The company shows strong revenue growth reaching $343M in 2025 with a 72% gross margin, though it continues to report net losses. Recent Q2 2026 results missed EPS expectations but beat revenue estimates, with management highlighting AI analytics platform growth and enterprise customer expansion as key drivers.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, investors face execution risks from persistent losses, negative cash flow, and ongoing fraud investigations. The stock's valuation appears stretched at 11.6x book value, requiring successful monetization of AI initiatives to justify current levels.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
